Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.

ABSTRACT: Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aeros

SUBMITTER: Corbett M 

PROVIDER: S-EPMC2538878 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature